ANNE PORTWICH

Anne Portwich is a distinguished Partner at EQT Life Sciences, a prominent global investment organization dedicated to advancing healthcare innovation. Based in Munich, Germany, Anne plays a pivotal role in identifying, evaluating, and nurturing promising companies within the dynamic life sciences sector. Her expertise spans a broad spectrum of healthcare sub-sectors, including biotechnology, medical technology, and digital health, where she focuses on firms developing transformative therapies, cutting-edge diagnostics, and innovative medical devices.

At EQT Life Sciences, Anne is instrumental in driving the firm's investment strategy, particularly in early-stage and growth-stage companies that are poised to make a significant impact on patient care. She is known for her rigorous analytical approach and deep scientific understanding, which enables her to assess complex scientific and clinical data to identify truly disruptive technologies. Her work involves close collaboration with portfolio companies, providing strategic guidance and leveraging EQT's extensive network to accelerate their growth and market penetration.

Anne's impressive career trajectory reflects a strong foundation in both science and finance. Before joining EQT Life Sciences (formerly LSP) in 2017, she honed her investment acumen as an Investment Manager at Wellington Partners Life Sciences. In this role, she gained valuable experience in venture capital, focusing on European life sciences companies. Prior to her venture capital career, Anne served as a consultant at McKinsey & Company, where she advised leading pharmaceutical and medical device companies on critical strategic and operational challenges. This experience provided her with a comprehensive understanding of the healthcare industry's commercial landscape and regulatory environment.

Academically, Anne holds a PhD in Molecular Biology from the prestigious University of Cambridge, following an MSc in Molecular Biology from the University of Vienna. This robust scientific background underpins her ability to delve into the intricacies of novel biological mechanisms and technological advancements, making her a highly respected figure in the life sciences investment community.

Throughout her career, Anne has been associated with several notable investments and successful exits. She currently serves on the boards of innovative companies such as Cardior Pharmaceuticals, ProteoNic, AAVantgarde Bio, and Lixte Biotechnology. Her past board roles include significant contributions to companies like Probiodrug (acquired by BioArctic), Prexton Therapeutics (acquired by Lundbeck), and NBE Therapeutics (acquired by Boehringer Ingelheim). Furthermore, she played a key role in the journeys of Pharvaris (NASDAQ: PHVS) and CureVac (NASDAQ: CVAC), both of which achieved successful public listings, underscoring her ability to identify and support companies with high growth potential.

Anne Portwich's dedication to fostering innovation in healthcare, combined with her extensive expertise and proven track record, positions her as a leading investor in the global life sciences arena. Her work at EQT Life Sciences continues to shape the future of medicine by backing companies that promise to deliver life-changing solutions to patients worldwide.